Dear Colleagues,
This week we anticipate welcoming 5,000 scientists, clinicians, industry professionals and others to the Society for Immunotherapy of Cancer’s 34th Annual Meeting & Pre-Conference Programs (SITC 2019) in National Harbor, Md. Our society and our Annual Meeting have been growing rapidly for two key reasons; the unprecedented success of cancer immunotherapy in the clinic, and the hope and expectations we all share that continued research in our field will produce more effective treatments for patients. From the small group that formed the society in the early 1980s, we have now grown to almost 3,000 members. By working together to promote research, education and the careers of our members, we can achieve the primary goal of the Society, which is to improve the lives of cancer patients.
At SITC 2019, we will once again gather together to hear and discuss the latest research and to develop new ideas and collaborations for the lab and clinic. The depth and quality of cancer immunotherapy research at our upcoming meeting is evident in the nearly 1,000 abstracts submitted to SITC 2019, as well as the SITC 2019 late-breaking abstract titles. The meeting organizers have worked diligently to bring the best science to the meeting, and to make the meeting a forum for discussion of the latest clinical advances. Along these lines, I’m excited to announce that we’ve added a new session to the 34th Annual Meeting programming on Saturday, Nov. 9, at 7 a.m., bringing together world experts to discuss the clinical implications of the most recent phase III immunotherapy trials in non-small cell lung cancer (more details are below). We hope you’ll join us!
On behalf of the society, I want to thank everyone who chose to bring their latest data to SITC 2019; I look forward to seeing your presentations this week in National Harbor and the engaging discussions that will follow.
Finally, I would also like to emphasize how much we value and appreciate the commitment of veteran and new members to our society. As we prepare to travel to National Harbor, I’d like to remind you that the 2019 SITC member dues cycle closes with the opening of our Annual Meeting & Pre-Conference Programs. Those who join SITC or renew their membership while attending SITC 2019 will receive the value of nearly 14 months of SITC membership. As a small token of appreciation, SITC members who renew their membership in National Harbor will also receive an exclusive SITC backpack and individuals who become a new SITC member will receive a society-branded water bottle. More information will be available when you arrive at SITC 2019 and receive your registration materials.
I look forward to seeing you all this week in National Harbor!
Sincerely,
Mario Sznol, MD
SITC President
This week we anticipate welcoming 5,000 scientists, clinicians, industry professionals and others to the Society for Immunotherapy of Cancer’s 34th Annual Meeting & Pre-Conference Programs (SITC 2019) in National Harbor, Md. Our society and our Annual Meeting have been growing rapidly for two key reasons; the unprecedented success of cancer immunotherapy in the clinic, and the hope and expectations we all share that continued research in our field will produce more effective treatments for patients. From the small group that formed the society in the early 1980s, we have now grown to almost 3,000 members. By working together to promote research, education and the careers of our members, we can achieve the primary goal of the Society, which is to improve the lives of cancer patients.
At SITC 2019, we will once again gather together to hear and discuss the latest research and to develop new ideas and collaborations for the lab and clinic. The depth and quality of cancer immunotherapy research at our upcoming meeting is evident in the nearly 1,000 abstracts submitted to SITC 2019, as well as the SITC 2019 late-breaking abstract titles. The meeting organizers have worked diligently to bring the best science to the meeting, and to make the meeting a forum for discussion of the latest clinical advances. Along these lines, I’m excited to announce that we’ve added a new session to the 34th Annual Meeting programming on Saturday, Nov. 9, at 7 a.m., bringing together world experts to discuss the clinical implications of the most recent phase III immunotherapy trials in non-small cell lung cancer (more details are below). We hope you’ll join us!
On behalf of the society, I want to thank everyone who chose to bring their latest data to SITC 2019; I look forward to seeing your presentations this week in National Harbor and the engaging discussions that will follow.
Finally, I would also like to emphasize how much we value and appreciate the commitment of veteran and new members to our society. As we prepare to travel to National Harbor, I’d like to remind you that the 2019 SITC member dues cycle closes with the opening of our Annual Meeting & Pre-Conference Programs. Those who join SITC or renew their membership while attending SITC 2019 will receive the value of nearly 14 months of SITC membership. As a small token of appreciation, SITC members who renew their membership in National Harbor will also receive an exclusive SITC backpack and individuals who become a new SITC member will receive a society-branded water bottle. More information will be available when you arrive at SITC 2019 and receive your registration materials.
I look forward to seeing you all this week in National Harbor!
Sincerely,
Mario Sznol, MD
SITC President
No comments:
Post a Comment